Interestingly, EGFR T790M mutations have recently been observed in biopsies of completely untreated primary breast cancer, indicating immediate drug resistance against most of the available EGFR targeting drugs in subgroups of MBC patients (Bemanian et al, 2015). This evidence concerns the gene EGFR and breast cancer.